THIS common condition may speed up Alzheimer's disease: Experts recommend a simple blood test to determine it
A recent study presented at the European Academy of Neurology Congress 2025 reveals that a blood test could predict rapid cognitive decline in early Alzheimer's patients. Researchers at the University of Brescia found insulin resistance, measured by the TyG index, significantly accelerates the disease's progression.
Alzheimer's disease, which is the most common type of dementia, is on the rise. About 57 million people had dementia worldwide in 2021, and the numbers are escalating. This progressive neurodegenerative disorder affects the quality of life, even impacting daily activities, and hence, early diagnosis is crucial.
Researchers have now found that a simple blood test may soon help doctors predict which patients with early Alzheimer's disease are most at risk of rapid cognitive decline. They also found that a common condition related to metabolic disorders could dramatically accelerate the disease.
The research was led by neurologists at the University of Brescia in Italy and was presented at the European Academy of Neurology (EAN) Congress 2025.
Common condition linked to accelerated Alzheimer's disease
The common condition in question is
insulin resistance
. The researchers looked at the records of 315 non-diabetic patients with cognitive deficits, including 200 with biologically confirmed Alzheimer's disease. All participants underwent a TyG index assessment and were followed clinically over three years.
The researchers found that the patients in the highest third of the TyG index within the Mild Cognitive Impairment-AD subgroup declined significantly faster than those with lower readings, losing more than 2.5 points per year on the widely used Mini-Mental State Examination.
The ratio for rapid progression was 4.08 (95% CI 1.06–15.73), which is a fourfold increase in risk.
'Once mild cognitive impairment is diagnosed, families always ask how fast it will progress. Our data show that a simple metabolic marker available in every hospital laboratory can help identify more vulnerable subjects who may be suitable candidates for targeted therapy or specific intervention strategies,' lead investigator Dr Bianca Gumina said in a statement.
Impact of
insulin resistance
on Alzheimer's disease
Though previous research has shown the association between insulin resistance and
Alzheimer's disease
, its role in how quickly the condition progresses has not been much explored. This recent study looked into insulin resistance's impact during the prodromal mild cognitive impairment (MCI) stage, when patients follow highly variable trajectories.
What is insulin resistance
Insulin resistance is a condition where the body's cells do not respond properly to insulin.
Insulin is a hormone produced by the pancreas that helps glucose (sugar) enter cells for energy. To compensate, the pancreas produces more insulin, but over time, this can lead to elevated blood sugar levels (hyperglycemia), increasing the risk of type 2 diabetes and other serious health conditions.
The study
The researchers used the TyG index, a simple and affordable way to measure insulin resistance, to see if metabolic problems could help predict how quickly cognitive decline happens after diagnosis.
'We were surprised to see the effect only in the Alzheimer's spectrum and not in other neurodegenerative diseases. It suggests a disease-specific vulnerability to metabolic stress during the prodromal window, when interventions may still change the trajectory', Dr Gumina added.
Salman Khan Drops Health Bombshell on National TV
The researchers at the University of Brescia, led by Professor Padovani and Professor Pilotto, found that high TyG was also associated with blood–brain barrier disruption and cardiovascular risk factors. However, it showed no interaction with the APOE ε4 genotype, and hinted that metabolic and genetic risks may act through distinct pathways.
'If targeting metabolism can delay progression, we will have a readily modifiable target that works alongside emerging disease-modifying drugs', Dr Gumina concluded.
One step to a healthier you—join Times Health+ Yoga and feel the change
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
4 hours ago
- Mint
Three siblings, one fatal gene: A family's fight against early-onset Alzheimer's
Hannah Richardson is hopeful about her future and its endless possibilities. But the 24-year-old's plans are clouded by an unthinkable reality—there is a 50% chance she will develop Alzheimer's disease in her 30s. Hannah's family has a history of a rare genetic mutation that, when inherited, virtually guarantees that the carrier will die of an aggressive form of Alzheimer's early in life. No drug has been found to stop it. But now researchers are exploring a new avenue: Could pre-emptive treatment slow or even halt the memory-robbing disease in people at high risk of developing it? Hannah and her two siblings will help researchers test that theory. They are enrolling in a new clinical trial led by doctors at the Washington University School of Medicine. As part of the trial, the siblings will finally find out if they carry the fatal gene. 'I don't know if being in the trial is going to save me or my siblings. But in my head, it's the least I can do. Research is how cures are found," said Hannah, who dreams of becoming a physician assistant and is applying to graduate programs. Her brother Jacob, 22, and sister Rylee, 19, are both in college. Unlike most cases of Alzheimer's, which are unpredictable, 'in this population we know who will develop the disease and when they will develop it," said Heather Snyder, senior vice president of medical and scientific operations at the Alzheimer's Association, a major funder of the trial. Doctors have identified over 300 inheritable genetic mutations that cause early-onset Alzheimer's. These rare genes account for less than 1% of people with the condition, but researchers say that studying families like the Richardsons can offer insights into how to prevent and treat Alzheimer's in everyone. Among the people in Hannah's family who carry a mutation in what is known as the presenilin-1, or PSEN1, gene, the average age when Alzheimer's symptoms start is 39, according to the family. The disease is aggressive once symptoms appear and the decline is swift, the family said. 'I call it the monster," said Mary Salter, Hannah's grandmother. Hannah's grandfather and three of his four brothers died of Alzheimer's in their early 40s, soon after developing symptoms. Hannah's uncle died last year of the disease at the age of 44. And Hannah's mother, Carrie Richardson, started showing subtle signs of the disease in her early 40s. Now at age 44, Carrie has started to decline mentally. Carrie's children remember vividly the day in 2012 when she learned she was a carrier of the PSEN1 mutation. Her eyes were red and puffy when she picked the kids up from school. Pressed by Hannah to tell them why, a sobbing Carrie told them the news in the car. The siblings, who were all under 12, remember crying, too, though not fully understanding why. Today, Carrie has memory lapses and sometimes struggles to communicate, her children say. Her worsening symptoms forced her to quit her job as a preschool teacher and this month, she started the process of leaving her own home to move in with Mary. Carrie and her brother enrolled in a clinical trial that began at WashU Medicine in 2012. That trial tested whether the early use of experimental drugs that target a sticky protein in the brain known as amyloid could slow the progression of Alzheimer's in people who carried PSEN1 mutations and other rare genes. Hannah's uncle hadn't been able to join an extension of the trial because his symptoms became too pronounced, but her mom continues to be a participant and receives a bimonthly infusion of an antiamyloid drug. In a paper published in Lancet Neurology in March that detailed interim results of the extended trial, WashU Medicine researchers said treating people like Hannah's mom with antiamyloid drugs before Alzheimer's symptoms began, delayed the onset of the disease—in some cases lowering participants' risk of developing symptoms by 50%. The first antiamyloid drugs were approved by the Food and Drug Administration in 2021. These drugs clear accumulations, or plaques, of amyloid in the brain, which researchers once thought could be the root cause of Alzheimer's. But some doctors have since questioned this hypothesis, as well as whether the benefits of these treatments outweigh their risks. The drugs don't stop Alzheimer's in its tracks and though they have shown to reduce cognitive decline in some large clinical trials, the slowing was modest at best, said Dr. Scott Small, a Columbia University neurologist. Carrie Richardson prepares to blow out candles on her birthday cake surrounded by her children and mother.A sign honoring Bryan Salter hangs on Mary Salter's home. 'The science now predicts that amyloid plaques are not the root source of Alzheimer's," Small said. Swelling and bleeding in the brain is a possible side effect of antiamyloid drugs. Rarely, people have died from this complication. In about half of all patients in the WashU Medicine study, some brain swelling and microbleeds were detectable in MRI scans, though researchers said about 95% of participants had no symptoms from the medications. Antiamyloid drugs remain the only FDA-approved treatment available that can change the course of Alzheimer's. Dr. Randall Bateman, a neurologist who led the WashU Medicine study, said early use of the treatments could improve their efficacy and safety. He said he remains optimistic that removing—or even preventing altogether—the buildup of amyloid could slow or even halt the progression of the disease. Hannah and her siblings believe that antiamyloid drugs have helped stall their mom's Alzheimer's. That belief spurred them to enroll in a similar WashU Medicine clinical trial—one that seeks to treat carriers of rare genes with a different experimental antiamyloid drug, called remternetug, many years before they develop symptoms and, in some cases, even before amyloid has built up in their brains. Drugmaker Eli Lilly, which makes the drug, said it works similarly to earlier antiamyloid treatments but has the benefit of being administered as an injection rather than an intravenous infusion. Rylee Richardson, a cheerleader and rising sophomore at Tulane University, said she and her siblings thought long and hard about participating in the trial. They ultimately decided that it was worth the potential risks. 'I will do anything that gives me and my siblings a better chance," she said. Until now, Rylee and her siblings had decided not to find out if they carry the PSEN1 mutation out of fear that it could upend their lives. But if they want to participate in the extended phase of the trial, they will have to learn the truth. The initial phase will last for two years and focus on basic efficacy and safety questions, said Dr. Eric McDade, a colleague of Bateman's who is leading the trial. Only people who test positive for a high-risk genetic mutation will be randomized to either receive a low dose of the active drug or placebo. For those who test negative, they can stay in the trial if they choose not to find out their genetic status and would be given a placebo. Dr. Richard Isaacson, a neurologist at the Institute for Neurodegenerative Diseases who isn't involved in the trial, said he believes antiamyloid drugs could be helpful in slowing cognitive decline when used preventively in patients at risk of Alzheimer's. He himself prescribes them to patients at his clinics in New York and Florida, but only in people who already have some amyloid buildup. He questioned whether it made sense to use these drugs in people who don't have amyloid at all. 'That is not something that sits well with me," said Isaacson. WashU Medicine researchers said that in animal experiments, antiamyloid treatments were most effective when used before evidence of amyloid buildup. But such an experiment has yet to be conducted in people. Alzheimer's has been a specter that has haunted the Richardson siblings since they were children. The three of them made a pact years ago to not have children if they learned that they carried the Alzheimer's gene. 'We decided that we would be the last three. No one has to suffer anymore from our family," Hannah said. 'We want to do everything we can to stop it for us and everybody else."
Time of India
8 hours ago
- Time of India
Alzheimer's disease: Common herbs used in the kitchen could help slow down the progression of the disease, study finds
Imagine a common sprig of rosemary or sage gracing your roast chicken! Now, imagine that this modest herb may harbor a powerful ally in the fight against Alzheimer's. Yes, that's right. Tired of too many ads? go ad free now Recent breakthroughs spotlight a compound called carnosic acid, an antioxidant and anti-inflammatory powerhouse present in these kitchen staples. In its natural form, carnosic acid is unstable, yet innovative science has transformed it into a stabilized prodrug, diAcCA, capable of crossing the blood-brain barrier and selectively activating in damaged, inflamed brain cells. While still in the pre-clinical stages, this discovery lights a spark of hope, hinting that everyday herbs might play a role in slowing, or even preventing, cognitive decline. What does the study say? In a recent study published in the journal Antioxidants, researchers from the Scripps Research Institute discovered a compound called carnosic acid – found in rosemary and sage – with impressive antioxidant and anti-inflammatory properties. They suggest that this compound could be beneficial for neurodegenerative disorders like Alzheimer's. Researchers Piu Banerjee and Dr. Stuart Lipton shared their findings with Fox News Digital. They said, 'In this study, we observed that administering this drug to mice that had advanced Alzheimer's-like disease significantly improved the number of neurons, as well as the number of synapses or connections between the brain cells.' They also noted, 'It reduced inflammation caused by current anti-amyloid antibody therapies and improved learning and memory behavior in the mice that received the drug.' Banerjee explained that carnosic acid is a 'prodrug,' meaning it's inactive until it enters the body, where it gets activated by oxidative and inflammatory stress. Tired of too many ads? go ad free now 'It specifically targets cells undergoing oxidative and inflammatory stress, without affecting healthy, normal brain cells,' she added. This makes it a safer option for treatment. The researchers believe carnosic acid might help reduce inflammation in aging brains. However, they urge caution. Courtney Kloske, director of scientific engagement for the Alzheimer's Association, stressed that while studying mice helps us understand the disease, we really need to conduct human studies for a complete picture. 'These findings are intriguing, but more research is needed to see how these compounds affect people living with or at risk for Alzheimer's,' she advised. Banerjee and Lipton also noted that just cooking with sage and rosemary won't deliver the same anti-inflammatory benefits. "Critically, one cannot take sufficient herbs safely to produce the same effect as our new drug,' Banerjee explained. Kloske added, 'At this point, no one should consume these herbs or carnosic acid to prevent or treat Alzheimer's or other cognitive impairments.' Origins and key compound: Carnosic acid in rosemary and sage Rosemary (Rosmarinus officinalis) and sage have both storied reputations—ancient scholars hung rosemary in their robes to boost memory. Modern research confirms that carnosic acid, alongside carnosol and rosmarinic acid, provides potent antioxidant and anti-inflammatory effects that can reach the brain. These compounds activate the Nrf2 pathway, which spurs the production of endogenous enzymes that combat oxidative stress – one of Alzheimer's disease's key drivers. From kitchen to Lab: Creating diAcCA Carnosic acid's instability limited its therapeutic potential – until researchers at Scripps created diAcCA, an acetylated prodrug version. When consumed, diAcCA converts into its active form in the gut, crossing into the bloodstream and, crucially, the brain. In mouse models mimicking Alzheimer's (5xFAD strain), three months of diAcCA treatment led to restoration of memory and learning to near-normal levels, increased synaptic density in hippocampal circuits, and reduced neuroinflammation and diminished amyloid-β and phosphorylated tau accumulation. These results were consistent across behavioral tasks, histology, and biochemistry, with no observed toxicity. Mechanisms at work: A multi-front attack diAcCA (and its metabolite carnosic acid) appear to combat Alzheimer's via several reinforcing mechanisms: Antioxidant defense: Activates Nrf2, turning on protective genes that tackle oxidative stress and stabilize cell redox balance. Anti‑inflammatory action: Blocks cytokine release (IL-1β, IL-6, TNF‑α) and inhibits inflammasome activation, reducing harmful microglial activity. Neurotrophic support: Boosts nerve growth factor, BDNF, and synaptic resilience. Cholinergic enhancement: Rosemary's 1,8‑cineole component inhibits acetylcholinesterase, helping sustain acetylcholine levels vital for memory. Reduced neurotoxic proteins: Helps clear amyloid‑β and tau aggregates via synaptic and inflammatory pathways. The future ahead: While diAcCA hasn't yet been tested in people, several encouraging signals emerge: FDA classifies carnosic acid as 'Generally Recognized as Safe', which may speed early‑stage trials. diAcCA appears well tolerated in mice, with even digestive system benefits, while smaller human trials using rosemary/sage extracts showed improved cognitive speed and memory performance in older adults. Meta‑analyses of animal studies reflect moderate‑to‑strong cognitive gains from rosemary extract. Banerjee expressed hope for the future, stating, 'I hope our drug will start human clinical trials soon. If it proves to be effective, it will be a great new drug for those suffering from Alzheimer's. We are cautiously optimistic for its success in human clinical trials!' Reduced risk of Alzheimer's disease linked to target protein for diabetes, as per a study
India Today
20 hours ago
- India Today
Your Brain on Sugar: What Really Happens Inside Your Head
Your Brain on Sugar: What Really Happens Inside Your Head By: Kashmik Singh Chouhan Sugar Lights Up the Brain But Not Always in a Good Way Your brain loves sugar but too much of it can cause problems. Here's what really happens when you eat sugary food or drinks. Glucose is your brain's main fuel. After eating sugar, your brain gets a fast energy spike making you feel alert and awake (temporarily). 1. Instant Energy Boost Sugar triggers dopamine—the 'feel good' chemical. It lights up brain reward centers, which is why sugar can feel addictive. 2. Dopamine Rush Once the sugar rush fades, your blood sugar crashes. This can lead to irritability, fatigue, and anxious feelings. 3. Mood Swings Too much sugar can disrupt how brain cells communicate. You may feel foggy, distracted, or have trouble focusing. 4. Focus & Brain Fog Diets high in sugar are linked to weaker memory and learning. Over time, sugar may shrink memory-related brain areas like the hippocampus. 5. Memory & Learning High sugar intake increases brain inflammation and raises the risk of depression, anxiety, and diseases like Alzheimer's. 6. Long-Term Impact Sweet, but at a Cost Sugar isn't the enemy but too much can affect how your brain works. Fuel your mind with balanced meals and keep sugar as an occasional treat.
